TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. reports a growing adoption of its Steriwave® light-activated antimicrobial therapy across various surgical specialties in the UK and Canada to reduce surgical site infections (SSIs). Steriwave is being used for nasal decolonization before major surgeries, offering a fast-acting, resistance-free alternative to current standards like mupirocin. The therapy is non-invasive, effective immediately, and allows the nasal microbiome to recover quickly. With its use expanding in major hospitals and ongoing clinical trials in the US, Steriwave is positioned to significantly impact infection prevention practices and enhance patient safety.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with approvals in several countries and ongoing clinical trials in the US.
Average Trading Volume: 157,802
Technical Sentiment Signal: Buy
Current Market Cap: £60.94M
For a thorough assessment of OBI stock, go to TipRanks’ Stock Analysis page.